Neil is Senior Vice President for the Philips business in Western Europe overseeing the UK, Ireland, Benelux and the Nordic regions. In his 25 years with Philips, Neil has held a number of leadership positions in the company. In his most recent role leading the UK and Ireland, Neil has overseen the transition from the company’s historical role as an electronics and lighting company to becoming one of the largest leading health technology companies focussed on supporting the health of the nation at every stage of people’s lives.
Under Neil’s leadership, Philips has led initiatives to reduce healthcare inequalities, accelerate wide-spread use of sustainable healthcare solutions in support of the NHS’ net zero target and championed the digitisation of the NHS through innovative solutions. This includes launching Philips’ Radiology Operations Command Centres and Community Diagnostic Centres in the UK, both of which will help alleviate the backlog of patients waiting for diagnosis and treatment.
In addition to his role at Philips, Neil is Chair of the Association of British Healthtech Industries.
Cristina Duran is the Chief Digital Health Officer R&D at AstraZeneca, responsible for harnessing the power of digital technology to accelerate the development and delivery of new medicines to patients. Under her leadership, the Digital Health R&D team has helped transform AstraZeneca’s core business and is delivering benefits at pace, including quantified improvement of patient experience on clinical trials, acceleration of research and millions in productivity savings. Cristina is passionate about innovation and increasing enterprise value through inspiring an organization to change for the future.
Cristina has worked at the company for over 10 years, holding leadership positions across global commercial, in country commercial and R&D.
Prior to joining AstraZeneca, Cristina worked as a senior management consultant in Accenture leading large transformation programs, including setting up a new tech company that is now one of the main brands for a large consumer company, leading Board level business transformation strategy reviews and leading the implementation of large transformations for telecoms companies.
Cristina is considered an industry expert in the field of digital health. She is a frequent keynote speaker at events such as Prix Galien, Digital Health World Congress and Pistoia Alliance. She currently serves on the oncology community advisory board of Health XL and is part of the Sustainable Markets Initiative task force focused on taking collective action to decarbonize healthcare.
Cristina resides in Cambridge, UK. She is Spanish and married with two children.
I lead on AMR and Vaccines at Innovate UK, developing & delivering funding calls, supporting workshops and strategy. This includes overseeing extant and new projects funded through IUK funding mechanisms such as the Biomedical Catalyst and SMART call. In addition, I am responsible for the delivery of the following projects focused relating to AMR and Vaccines:
• China-UK AMR call. Funded by DHSC (GAMRIF-ODA)
• AMR in Humans. Funded by DHSC (SBRI)
• Various Vaccine calls: Funded by DHSC (SBRI)
I work widely across government and am actively involved in initiatives such as the UK AMR Diagnostics Programme Board and AMR Funders Forum.
Prior to this, I held various research and research management positions within the public sector. Most recently, I managed a research programme for Dstl that included the development of medical countermeasures against biological and chemical agents, diagnostics, trauma care, regenerative medicine and hearing loss. My first job at Dstl was the management of the UK plague vaccine programme. Previous to this I worked at CAMR where I completed a Ph.D and post-doctoral research in cancer and biofilms before moving into ECACC as Quality Manager
Area of Interest:
New solutions to extant problems, e.g. Flu
Michael Lewis, is Director for the NIHR i4i and SBRi Healthcare programmes, as well as being Professor of Life Science Innovation at the University of Birmingham.
Michael has had an extensive industrial background in life sciences and digital innovation in healthcare having previously held senior roles at Align Technology (Amsterdam), Boston Scientific (Paris), C.R. Bard (New Jersey), Sybron (Switzerland), and Becton Dickinson (UK) and was President of Gambro (Sweden) in the £3bn public to private buyout.
Michael has worked for numerous private equity and venture capital organisations and has a deal sheet valued at over $5bn including IPOs in London and New York.
His industry experience covers pharma, biotech, digital, dental, devices, clinical trials, and diagnostics. Currently, he is Chair of 4 life science companies all with a real emphasis on citizen-focused, data and outcomes-driven healthcare. He also sits on the Board of SNOMED, the global medical coding standardisation system, and the Executive Board of Birmingham Health Partners.
At the University he lectures on innovation in life sciences and how this aligns with the United Nations 17 Sustainable Development goals and the circular economy. He is also closely involved with delivering the new Birmingham Health Innovation campus, a £270m life science park under construction between the University of Birmingham and University Hospitals Birmingham.
27 years in Medical Devices. MD of Surgical Holdings, manufacturer & repairer of surgical instruments/endoscopes. Chair of ABHI surgical instrument group and V Chair Sustainability Group.
After studying Philosophy and Management at the University of Leeds, Addie undertook a Masters in Sustainability and Management at Royal Holloway. In becoming ABHI’s first Sustainability Executive, Addie will lead the Association’s work on this critical agenda, providing support to the membership and working with stakeholders to ensure the role of sustainability within HealthTech is recognised. ABHI has also produced a Sustainability Framework for Action, developed to aid ABHI members with their own sustainability journey.
Michael is a co-founder of Lindus Health. Lindus Health’s mission is to enable an order of magnitude change in the scale, frequency and cost of clinical trials. We help sponsors design and deliver faster clinical trials and studies, and our recruitment technology can help trials quickly find, screen and recruit the right participants to hit full enrolment. We’ve partnered with academics, CROs and pharma companies to deliver for 20+ clinical trials based in the UK.
Paul Wicks, Ph.D., is a neuropsychologist and independent consultant in digital health, clinical trials, rare disease, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 750,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul has over 160 publications including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome (PRO) measures, a “dose-response” curve for the benefits of friendship between patients, virtual clinical trial designs, and applications of artificial intelligence (AI).
He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease. His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.
Dr Beverley Vaughan joined the Arise Innovation Hubs as Director in June 2021, with over 20 years’ experience in the healthcare and life sciences sector.
Beverley trained as a clinical scientist in Haematology and working at Cambridge and London University Hospitals.
Working in the innovation sector for the last 10 years with roles in Stevenage Bioscience Catalyst (SBC), Cell and Gene Therapy Catapult (CGT) and the University of Oxford in programme manager and director level positions.
Whilst at SBC Beverley supported the development of translational research facilities and raised funding from multiple pharma and biotech companies for the Open Innovation Challenge in Neurodegeneration. At CGT Beverley managed a wide portfolio of project from novel drug discovery spin outs to NHS led delivery of cell therapy products. Most recently she was responsible for the delivery of a drug discovery consortium-UKSPINE- pivoting traditional pathways to meet the demands of healthy aging with partners, Universities of Oxford, Dundee and Birmingham, Medicines Discovery Catapult, The Francis Crick Institute and Sanger Centre Cambridge.
Since joining Arise as Director Beverley has been working on building the life science strategy for their newest hub located on the Harlow Innovation Park, leading on strategy, fund raising and partnering activities to build a cluster of expertise within this synapse of the London-Cambridge corridor. She is also a member of the NC3Rs CRACKIT advisory panel.
Meri is a co-founder of Lindus Health. Lindus Health’s mission is to enable an order of magnitude change in the scale, frequency and cost of clinical trials. We help sponsors design and deliver faster clinical trials and studies, and our recruitment technology can help trials quickly find, screen and recruit the right participants to hit full enrolment. We’ve partnered with academics, CROs and pharma companies to deliver for 20+ clinical trials based in the UK.
Meri was previously a venture capital investor and partner to biotech and digital health companies. He took part in the COVID-19 vaccine trials as a volunteer, where he saw how trial outcomes could be improved by focusing on patient experience
Peter has helped build multiple high-growth biomedical businesses, commercializing innovative products for surgery, diagnostics and digital treatment pathways in multiple international markets and leading R&D, regulated product development and strategic business development.
He founded Romilly Life Sciences to help health, tech and pharma organizations implement evidence-led digital product strategy, including technologies such as artificial intelligence, supported by effective cross-sector collaboration frameworks and coaching.
He is also co-founder of Migration Biotherapeutics, Honorary Professor at the University of Birmingham Centre for Regulatory Science and Innovation, Fellow and Chair of Healthcare at the Institution of Engineering and Technology, an Academy of Medical Sciences Future Leader in Innovation Enterprise and Research (FLIER) and works with HDRUK and NIHR to support leadership development and R&D funding programmes.
For the last couple of years Phil has had the pleasure of working with colleagues and stakeholders in developing High-Tech. regional innovation clusters, in key strategic sectors for the UK. This includes setting up and leading the North West of England’s Health and Life sciences Cluster (HealthTech) and establishing other clusters in sectors such as Space.
The clusters exist to connect key capabilities between stakeholders, national science facilities and innovators in the wider ecosystem to support collaboration, cross-sector innovation and community building.
A scientist by background, he undertook a PhD for the European Space Agency at King’s College London, conducting numerous studies on a SkinSuit which was designed to support astronauts in space and reduce the risk of spinal issues post flight. This has subsequently been used on several astronaut missions.
Passionate about cross sector opportunities, including Health & Space, for 5 years he coordinated the UK’s Space Life and Biomedical Science Association, which among other core activities he led the development of the UK Position Paper ‘Why Space? The opportunity for Health & Life Science Innovation”. He currently chairs the UK’s Regional Space Cluster Advisory board and at a European Level serves as the elected President for the European Low Gravity Research Association (ELGRA).
Louise joined Eastern AHSN as Commercial Director in February 2019. By understanding the challenges and healthcare landscape of the Eastern region we connect industry, academia, third sector and health and social care services to identify and support ideas that meet the needs of the NHS. Louise joined Eastern AHSN from the Johnson & Johnson Innovation Centre in London where, as Senior Director of Immunology Scientific Innovation, her main responsibilities were to identify the best opportunities for value-generating collaborations, and support development of an industry-leading Immunology portfolio of investment opportunities across Europe.
Prior to this Louise held a number of positions at Janssen within the commercial business in the Medical Affairs function of the Immunology Therapy Area in the UK and Europe.
Louise joined Janssen in May 2008 following a successful research career in both academia and industry. After completing her PhD in Immunology (Imperial College London), Louise undertook a post-doctoral fellowship at Harvard Medical School (Boston). From there Louise worked at Celltech/UCB in Cambridge for 6 years as a senior pharmacologist, leading a team responsible for developing preclinical models of inflammation to support small molecule discovery research, whilst also leading the psoriasis research strategy.
Dr Neil Ebenezer is the Medical Technologist and Genomics Specialist at Department for International Trade. He joined the Life Science team in 2019 and his role includes developing and implementing the global strategy for medical technologies and genomics across inward investment and exports. Neil has a broad scientific knowledge with a degree in Biotechnology from Dublin City University. He obtained a PhD from the Institute of Ophthalmology (UCL), on the genetics of ocular diseases. Neil then held various posts within the civil service, including; the Department of Health, the Medicines & Healthcare Products Regulatory Agency (MHRA) and at the Department of Transport. Subsequently, Neil was the Director of Research, Policy and Innovation at the charity Fight for Sight before joining DIT.
Vishal joined BSI over 7 years ago and is currently the Head of the UK Approved Body and a Senior Regulatory Lead for Medical Devices. He is responsible for the regulatory oversight of the Medical Devices Approved Body and wider BSI strategy, policies, procedures, and documentation to meet the various legislative and designation requirements. Prior to his current role, he has been a Regulatory Lead, Technical Team Manager, Technical Specialist & Scheme Manager with expertise in Active Devices.
Vishal holds a Masters in Medical Engineering from Queen Mary University of London and has over 10 years’ experience with medical devices working within industry, third party testing and Notified/Approved Body.
Stephen is a patent attorney with over 20 years of experience in drafting, prosecuting and contesting patents and advising clients ranging from local start-ups and SMEs, through universities in the UK and elsewhere, to multi-national companies. With a background in physics and a leaning towards the mathematical side of that, a significant portion of Stephen’s work has been in the MedTech field. This has ranged from devices and analytics to the application of computation solutions in bioinformatics applications such as genomics and computational approaches to diagnosis and drug discovery.
Brennan is an accomplished medical device expert with an extensive background in managing and delivering innovative, high-value programmes across a range of medical technology and pharmaceutical delivery routes. These include infusion, injection, intranasal, implantable, ocular, oral, respiratory and topical applications. He also has hands-on experience of gaining device approval within the regulatory frameworks.
With his direct experience of product development and industry knowledge, Brennan co-ordinates Team Consulting’s drug delivery activities to ensure we continue to create exciting technologies, develop more sustainable medical products and deliver exceptional services for our clients.
Prior to his appointment at Team, Brennan worked on the development of medical devices for a large pharmaco as well as in other sectors for several multi-national companies. Brennan has a BSc (Hons) degree in Product Design and Engineering and is the named inventor on several patents.
Currently on a mission re Environmental Sustainability. Net zero a must.
20 plus years in Medical devices: sales, management, marketing, Market Development & Market Access.
PG Diploma in Health Economics York University gave me a platform to move into Health Economics, Policy and Reimbursement. My work in Public Affairs is now linked to my focus on Environmental Sustainability.
I chair the ABHI Sustainability group, Vice-chair the Commercial policy group, and sit on the Board of HealthTech Ireland.
Passed course from University of Cambridge course on Business and Climate Change : Towards Net Zero Emissions – Very inspiring!
John spent nearly a decade in industry developing molecular diagnostics and is now head of the North East Innovation Lab, part of Newcastle Hospitals. The Innovation lab works with diagnostic test developers to provide them with the facilities, samples and expertise they need to accelerate development. Originally part of the Integrated COVID hub North East the labs work has now expanded to support diagnostics for other disease areas too.
Rahul is the director of Health Tech business at CPI, which offers end to end innovation development services. We work with mature companies and start-ups to develop transformative ideas into commercial products.
He has 15+ years of global experience working for Johnson & Johnson and Unilever. At J&J, Rahul led growth of medical devices within cardiovascular across EMEA. He worked on the adoption of innovative mental health and infectious pharmaceutical treatments in the NHS.
Recently, at Medicspot, a digital health company, Rahul has been working as the Chief Commercial Officer. Medicspot is creating digital technologies that will improve access and efficiencies within primary healthcare space so everyone can access the right care at the right time. Rahul worked on building up Arc Health, a digital technology business and helped grow Medicspot’s primary healthcare business.
He holds an MBA from London Business School and a Chemical Engineering degree from Indian Institute of Technology, Delhi.
Juhi Tandon has been a practicing NHS doctor since 2005, and is Co-founder and Medical Director for Cognitant Group, a health technology company whose mission is to help people better understand their health, through immersive technology. Juhi is passionate about preventative health, reducing health inequalities by overcoming language and literacy barriers and empowering patients to make informed decisions about their care.
Nina is the co-founder and CEO of Avenna Ltd , a medtech company specialising in the development of precision medicine technologies for Chronic Inflammatory Diseases (CIDs).
Her mission is to make healthcare for CIDs more preventive and personalised. This can be achieved by developing more effective, affordable, and accessible precision medicine solutions, which enable early detection and treatment personalisation for CIDs. She has a background in finance, business, and healthcare and worked in large multinational companies including Nomura, Bloomberg and Schlumberger as well as several entrepreneurship ventures. Her first company, Wellcode Life is a scientific wellness company which provides integrated health transformation programmes tailored to an individual’s unique molecular, genetic and physiological profile.
Nina’s main ability and expertise is to connect clinical, science and business worlds. She uses wealth of experience to translate the most promising research-grade technologies into practical solutions for individuals, clinicians, and biopharma. This includes design and execution of clinical studies and trials, developing informatics infrastructure to facilitate the delivery of precision health programs for chronic disease prevention.
Sandeep Konduru is the founding CEO of RUMI Medtech Limited. Its flagship product REMCARE is helping hospitals tackle elective backlogs through digital transformation of clinical pathways. The product has won several competitions and awards since its release and is gaining significant traction in the NHS.
Sandeep is a practising Orthopaedic Spine Surgeon. His experience in the NHS motivated him to create REMCARE in association with clinical colleagues to improve workflows in the NHS thereby improving patient outcomes, increasing throughput while decreasing staff burden. Sandeep is also a reviewer for the NIHR and has extensive experience in improving patient pathways in clinical practice. He also has significant research interests and is a Honourary Senior Clinical Lecturer at Keele University.
Emanuela is the Co-Founder of Prosoma, a company that’s creating bespoke digital therapeutics solutions for oncology. Her interests lie in tech, especially Femtech and Medtech, and mental health.
Following years of experience with the NHS and NIHR, she was keen to start her own project in mental health, where support is especially key.
Prosoma develops scalable mental and behavioural support solutions for cancer patients. Their first app, Living Well, is designed to improve patient’s quality of life and reduce stress, anxiety, and depression symptoms related to their diagnosis and various stages of treatment. Following clinical trials and initial partnerships with insurers and pharma companies, Prosoma is now seeking Series A investment.
Georgina is a data scientist who has spent her career developing AI-driven health technology. She holds a Master’s in Medical Robotics from Imperial College London and led GSK’s first data-driven clinical trial using remote monitoring to predict patient outcomes at McLaren Applied Technologies. As Head of Data Science and part of the Executive Team at Touch Surgery she built, grew and managed technical teams to deliver data-driven products.
Mina is a global legal expert with 20 years’ experience advising healthcare organisations on legal issues and calculated risk-taking including: agile risk management, good governance and ethical design thinking. Mina has dedicated her career to partnering with healthcare organisations to move forward, create value and ultimately, help patients. She is an accomplished problem solver who helps companies to move fast while avoiding the mistakes that hold others back. Mina is a US qualified lawyer, based in London, working globally with healthcare companies on risk and compliance. Working with start-ups through to large corporations, Mina has an innovative and practical approach, giving clients a broad understanding of their risk portfolio to catalyse decision making. Mina’s focus is to minimise downside risk and optimise opportunities, all while keeping her clients safe from the myriad of legal and reputational risk that surrounds the health industry. She was formerly the Global Privacy Officer, R&D Compliance Officer, Head of Global Risk and Head of Digital Risk at GSK.
Prof. Camille Carroll is Professor of Clinical Neuroscience at the University of Plymouth, leading the Parkinson’s service in Plymouth to 3 national awards. Her research is focused on disease modification and the use of digital health technologies for monitoring and personalized care in Parkinson’s. Prof. Carroll was the chief investigator of a multi-centre clinical trial of simvastatin as a disease modifying agent in Parkinson’s disease (PD STAT). She co-leads the Edmond J Safra ACT-PD initiative, developing a multi-arm, multi-stage trial platform for disease modifying interventions in Parkinson’s. She is the NIHR CRN National Specialty Lead for Neurodegenerative Diseases, overseeing a balanced clinical trial portfolio in neurodegenerative disorders. She leads the CRN Remote Methods of Trial Delivery working group and was a steering group member for NIHR Include. She is Clinical co-Director of the Parkinson’s Excellence Network in the UK and has been internationally recognized for her patient-centred approach, broadening the opportunity for Parkinson’s research and improving support for patient care and self-management.
Dr Harvey is an experienced clinician and health technology consultant. He is a board certified consultant radiologist and academic, trained in the NHS and Europe’s leading cancer research center, the Institute of Cancer Research, where he was twice awarded ICR Science Writer of the Year.
He has held leadership roles at two flagship UK startups, leading to successfully gaining the world-first CE marking for an AI-supported triage service, and the first UK CE mark for a deep-learning medical device.
He was a co-opted member of the Royal College of Radiologists informatics committee and sat on their AI policy reference group. He also acted as co-chair to the Topol health technology review for Health Education England commissioned by the Secretary of State for Health and Social Care, and sat on the editorial board at Nature: Digital Medicine.
He now serves as Managing Director at Hardian Health, a multi-disciplinary digital health technology consultancy, and holds an honorary research fellowship at the Institute of Cognitive Neurosciences at UCL.
I am a seasoned expert in global health economics, market access, reimbursement, and health policy. My focus areas include digital health, digital therapeutics, medical/surgical robotics, oncology, radiation oncology, neurology, neurosurgery, urology, lab & diagnostics, companion diagnostics, diabetes, cardiology, infectious diseases, artificial intelligence, rare diseases, and durable & medical equipment.
Emilė Radytė is the Co-founder and CEO of Samphire Neuroscience, a medical device technology company building wearable solutions for neglected women’s health needs. She is a neuroscientist by training (Harvard College ’20, Oxford ’21, ’24) and has experience working in academia, public health and emergency medicine.
Award-winning dietitian experienced in working in a variety of industries including digital health, clinical practice, consultancy and in the media.
Background as television presenter / expert – including as series dietitian for BBC1’s Eat Well for Less, on channel 4’s Jamie’s Sugar Rush, and for completing two series as resident dietitian and feature co-presenter of the weekly health panel on ITV’s The Alan Titchmarsh Show. Co-presented channel 4’s prime time show, The Food Hospital and co-authored the book accompanying the series.
VP clinical for Oviva – accountable for the development of evidence-based digitally-enabled behaviour change programmes, establishing organisational quality assurance and clinical safety processes and leading company wide research and evaluation.
Director of Nutrifit Health, offering private consultations to members of the public at Spire Gatwick Park Hospital and communications advice to industry. Remote consultations and digital coaching also provided as part of private practice. Registered with all major health insurers and able to accept self-referrals.
Additional interests include clinical research, having previously completed and being awarded Master of Clinical Research from the University of Manchester and innovation around care models and modes of delivery.
Media spokesperson for the British Dietetic Association, Sense about Science and the Almond Board of California , regularly appearing in the media; on TV, radio and written press. Invited as a motivational speaker to events to highlight the potential influence of lifestyle change or the influence of nutritionists and dietitians in altering disease risk.
Specialties: Meeting Weight loss goals, behaviour change strategies, digital health, Bariatric surgery, infant nutrition, nutrition support, healthy eating guidelines, diabetes, cardiovascular disease, women’s health, cancer, gastrointestinal conditions including IBS, coeliac, IBD and diverticular disease, allergies and intolerances.
Steve is responsible for the strategic direction of CPI’s Electronics business unit and the organisation’s interaction in the Healthtech sector.
Steve’s expertise lies in the areas of sensing, diagnostics, wearables and digitally connected medical devices. Steve has delivered on a number of successful private projects at CPI, helping new research ideas develop through to commercial deployment. Clients include industries such as automotive, aerospace, defence, packaging and medtech. These projects involve working with companies of all sizes ranging from large corporates to SMEs and academia.
Prior to Strategy, Steve held Business Development and Marketing roles at CPI and is currently undertaking an Executive MBA at Warwick Business School.
Monica is currently supporting a range of UK / global projects focussed on data / digital innovation in Respiratory Health / Multiple LTC. After leaving GSK in January 2020 where she was a Medical Expert in the Global Respiratory Franchise she set up her own company MonFletch Consulting Ltd. She has been involved in influencing national and international policies through her extensive advocacy activities for a range of organisations including: WHO’s Global Alliance Against Respiratory Disease (GARD), the European Respiratory Society, the American Thoracic Society, the European COPD Coalition, and the International Primary Care Respiratory Group. She was Chair of the European Lung Foundation (2010-2014) and in that role advocated for wider patient engagement in all aspects of respiratory care & research. Her clinical interests are Asthma and COPD and how data and technology can be used to improve HC systems and patient outcomes. She believes that working in partnership with patients and enabling them to take greater control of their condition is key to improved outcomes.
Will joined Downing in August 2018 where he directs the healthcare activities of the Downing venture funds. Will has over 30 years’ experience in healthcare and biotechnology with over 18 years’ experience in venture capital across Europe and the US. After studying in Glasgow and Dundee he did 7 years post-doctoral research at the University of Munich before joining London based biotechnology company Antisoma. He then moved to Brussels where for over 10 years he ran the healthcare investments for Quest for Growth a large pan European cross over fund.
Dr. Samantha Westgate serves as the CEO of Perfectus Biomed Group, a leading provider of standard and customised microbiological testing services. Sam is recognised for her passion in designing innovative and bespoke microbiological services to support companies to develop products that improve lives. Following her PhD in wound healing at the University of Liverpool, Sam consulted for a start-up microbiological research company and relished being in the business world and applying her scientific knowledge. Sam founded Perfectus Biomed in 2012 and in 2020 she completed her first merger with a US based laboratory, positioning Perfectus Biomed Group to service clients globally.
Anthony Finbow is CEO at Eagle Genomics, a pioneer in the application of network science to biology across key industries such as Food & Nutrition, Beauty & Personal Care, AgBio and BioPharma. He has worked for over two decades as a leader, building and scaling deep technology businesses, and has a particular enthusiasm for businesses operating at the intersection of life science and data science. Anthony is currently Vice Chairman of the UK BioIndustry Association (BIA)’s Genomics Advisory Committee. He is also on the Executive Committee of the UK Knowledge Transfer Network (KTN) Microbiome Innovation Network, set up to develop a proactive, self-sustaining microbiome community in the UK and to raise the visibility of the UK’s world leading microbiome science.
As Executive Chairman and CEO, Anthony has built and exited a number of intellectual property rich B2B software companies. In particular, he was responsible for the turnaround, strategic repositioning and sale of private venture backed communications software company, Psytechnics to US Nasdaq-listed NetScout. Similarly, as Managing Director of MetaSolv, he was responsible for doubling the size of the European business, prior to that company being acquired by Oracle. In his early career, Anthony worked as an aircraft engineer and in industrial lasers and electro-optics. He trained as a lawyer and worked as a banker in the privatization of former East German industrial companies, before moving into leadership roles with technology businesses.
Julia is the Design Innovation Lead for innovateuk’s Health Ageing Challenge. She began her career as a software engineer in investment banking, progressing to Vice President, Equities Technologies at Credit Suisse before moving to the New Business division to set up new trading services bank-wide. Julia’s career then transitioned to social purpose business start-up and was recognised as the University of East Anglia’s Graduate of Global Distinction (2018) for her award-winning efforts in humanitarian engineering and contribution to services for people with cognitive impairment. Julia is a director trustee for Citizens Advice (CADAT) and an associate tutor for the UEA (lecturing in finance and information systems) and is a member of the Institute for Electrical and Electronic Engineers (IEEE.org – Advancing Technology for Humanity). Julia wrote the foreword for the upcoming Co-Creation Guide for the Alzheimer’s Society Longitude Prize.
Kathryn is a respected and successful change leadership expert, with diverse career experience in Europe and North America. She has over 25 years of consulting and line experience with leading organisations (Unilever, Mars, KPMG and GSK). Since 2007 she has been leading her own independent consulting business, primarily working within the Life Sciences sector. By partnering with leaders at all levels within the sector, growth and sustainable success has resulted for the organisations she has worked with. She has recently published a book – “Leading for Change: How to thrive during uncertain times”.
She provides each organisation the approaches they need to meet their unique situation. Tailored approaches are used to develop a consolidated understanding of their environment and the priority challenges they face. This provides the basis for facilitating customised workshops where leaders not only create a desired future, but are ready to move forward and implement their ideas. Working with individual leaders or teams she advises how to bring other stakeholders with them so they achieve success together. These practical and supportive approaches create focus, accountability and collaboration across organisations and their partners. Organisations are left with an increased leadership capability and tangible business results.
After studying medicine in Belfast, Northern Ireland, Robbie started off his career in London, where he completed his foundation training and took up a trainee role in emergency medicine.
He was 3 years into his training when he decided to pivot into the tech space, applying his experience on the front line to the digital health space as the Clinical Safety Officer for Huma.
He’s now a qualified health and wellness coach and leads the team of health coaches at Surgery Hero, enabling patients to take an active role in their surgical experience – helping them to achieve better outcomes and reducing the burden on the healthcare system.
Graduated from Queen’s University Belfast in 2014
Completed foundation training in London before taking up a role as emergency medicine trainee in North Central London
Completed 3 years of training before moving into digital health as Clinical Safety Officer for Huma (then Medopad)
A qualified health and wellness coach, Robbie now leads a team of health coaches at Surgery Hero who work with patients to help them actively prepare for and recover from surgery at home.
Michael is Director, Medical Technologies EMEAA for Element Materials Testing which is a global testing, inspection, calibration and certification business. Element work with a broad range of health technology businesses to proactively support them to get to market and manufacture products that are as safe as practically possible.
Previously, Michael worked for Innovate UK for four years as a Health Innovation Lead and was responsible for the management of a UK government grant funding programme called the Biomedical Catalyst that provided £30M per annum to supports UK SMEs developing innovative health & life science products. Before joining Innovate UK, Michael was a Group Manager at Medicines & Healthcare Products Regulatory Agency (MHRA) where he led a team that was responsible for safety & surveillance of all medical devices in UK. He also spent 10 years in the medical device industry in a range of commercial roles working for Guidant, Boston Scientific and BIOTRONIK where he was Country Director UK & Eire.
Tim has a proven track-record in developing and translating technologies for medical devices. He specializes in bioengineering technology with an emphasis on sensors, interface electronics, and control algorithms.
Prior to joining Oxford, he was the Vice President of Research and Core Technology, Implantables R&D, for the Restorative Therapies Group of Medtronic. He was named a technical fellow in 2010, received Medtronic’s highest technical and scientific award, membership in the Bakken Society, in 2012, and the Wallin Leadership award in 2014. Tim was recently named to the College of Fellows for the American Institute of Medical and Biological Engineering. Prior to joining Medtronic, he worked as a Senior Design Engineer with the Micromachined Products Division at Analog Devices.
Outside of work, he is a frequent academic guest lecturer on neural engineering circuit designs and applications. He also serves as an associate editor of the IEEE Transactions on Biomedical Circuits and Systems, an associate editor of the IEEE Transactions on Biomedical Engineering, and sits on the editorial board of the Journal of Neural Engineering. Tim served on the program committee for the IEEE International Solid-State Circuits Conference (Imagers, MEMS, Medical and Displays) from 2008-2011.
Cynthia Bullock leads the innovation activities across the UK Government’s £98 million Healthy Ageing Challenge supporting the development and delivery of products and services that will allow people to remain active, productive, independent and socially connected across generations for as long as possible.
Cynthia has a background in health research, innovation and commercialisation having trained initially as a Biochemist and Molecular Biologist. Most recently, she led the delivery of Health and Life science programmes at Innovate UK, the UK’s innovation agency representing over £400 million of investment across therapeutics, MedTech, diagnostics and digital health technologies. Cynthia has an executive MBA.
John has 25 years’ experience as a start-up executive, board member, venture capital investor and investment banker specialising in the life sciences sector across the UK, Europe and the USA.
John is a Partner at Downing LLP, where he serves as Co-Head of Healthcare Ventures. Before that, he helped create Quanta Dialysis Technologies as an industrial spin-out from IMI plc in 2009 as an investor and founding board member. From 2014, he served as Quanta’s CEO for 8 years, where he transformed the company from an early-stage UK R&D team to an emerging global leader with transatlantic operations, a world-class team and an award-winning, portable haemodialysis system poised for market disruption. During his tenure, Quanta commercially launched its offering in the UK and US markets, while raising nearly $400 million in funding and securing the prestigious MacRobert Award for engineering excellence.
Previously, John was an Investment Director at NBGI Ventures, where both as a board member and an investor he was closely involved with a range of innovative medical technology companies in Europe and the US. Before that, John was an executive at the venture-backed start-up Nitec Pharma, an investment professional at Atlas Venture and Kirkland Investors, and an investment banker at Nomura and Lehman Brothers.
John is a graduate of the University of Chicago and previously served on the i4i selection panel for translational research at the National Institute for Health and Care Research (NIHR). He currently serves as an independent Board member at Otivio AS and is a mentor at the Enterprise Hub of the Royal Academy of Engineering.
Doris-Ann Williams has been Chief Executive of BIVDA since October 2001. She has over 40 years’ experience in the IVD sector. She has held a variety of roles; initially in R&D and subsequently in commercial roles including international responsibilities. She has been involved in a number of Government steering groups and boards including the Pathology Quality Oversight Group.
Doris-Ann was awarded an MBE in January 2011 and was recognised as a Friend of the Royal College of Pathologists in November 2012 and as a Friend of the Association for Clinical Biochemistry in July 2015. Doris-Ann also was elected as a Vice President of the Parliamentary & Scientific Committee in 2015 and is Chair of the organising committee for STEM for Britain 2022. Doris-Ann has particular interest in the role of diagnostic testing in the community and how diagnostics can help with mitigation of antimicrobial resistance.
A true scientist at heart passionate about healthcare & product development.
10 years of research experience in academia and industry. I work closely with product developers, funding organisations and the international community to develop new treatments and diagnostics for infectious diseases. Avid hiker and runner ! Love travelling !
I am a dynamic and experienced leader with expertise spanning both academia and industry. I have held leadership positions at a number of Russell Group Universities and am currently a Centre Director at the University of Birmingham. Additionally I am Co-Founder and Managing Director of Neuronostics Ltd, an awarding winning SME developing decision support systems for neurological conditions.
As managing director of Neuronostics Ltd, I am the strategic lead for the company with overall responsibility for leading the development and commercialisation of its clinical decision support systems and at-home monitoring tools. The company has recently moved its HQ to Bristol, where we are fortunate to be part of the SetSquared community. The potential of our products has been recognised regionally (Medilink SW StartUp award 2020, TechSW Best Healthcare 2020, Medilink SW Innovation award 2021) and nationally (Medilink UK StartUp 2020). To date we have secured over £1.5M in non-dilutive funding and £500K in dilutive funding to support the company’s growth.
Dr Cecily Morrison, MBE is a principal research manager at Microsoft Research in Cambridge. She leads the Teachable AI experiences team driving innovation in AI experiences intended to enable the future of inclusion. Most recently she has been working on the PeopleLens and Find My Things experiences for people who are blind or low vision. She is also committed to supporting Responsible AI processes and policy work to ensure the most productive use of Artificial Intelligence in our society. Cecily was named on the Queens Birthday list in 2020, receiving an MBE for Inclusive Design.
Mark Duman MRPharmS brings over 30 years of clinician, management consultant and patient perspectives to the healthcare, life sciences and digital health sectors. As the Chief Patient Officer for MD Healthcare, he works with organisations such as AstraZeneca, Diabetes UK, Google Health, JnJ, Macmillan Cancer Support, Microsoft, the NHS, Pfizer, Novartis & Siemens Healthineers to harness digital health, develop markets and improve patient engagement.
In short, to make healthcare more person-centric.
Dr Lloyd Humphreys is the Managing Director of Cogniss – the world’s first no-code platform for digital health. By training, Lloyd is a Clinical Psychologist with a business degree from the European School of Management and Technology in Berlin. He has developed (Breaking Free Online), delivered and globally scaled a number of digital health solutions, from personal health records (Patients Know Best), digital therapeutics (SilverCloud Health) and digital health formularies (ORCHA). Through this work, he has been acknowledged as one of the Top 100 Health Tech Influencers and recognised by the National Health Service for his involvement in bringing innovative technology solutions to the market. He was awarded one of the first NHS Innovation Accelerator (NIA) Fellowships.
Caroline is CEO and Co-Founder of Neu Health. Neu Health is a healthtech spinout from the University of Oxford dedicated to making the latest Parkinson’s disease and dementia care accessible for all. Building on 10 years of research and clinical validation by neurologists, neuroscientists and data scientists, Neu Health’s digital platform uses artificial intelligence and machine learning, to enable clinicians to assess disease progression, improve condition management, reduce clinician burden and ultimately improve outcomes.
She was previously Entrepreneur in Residence at Oxford Science Enterprises and Chief Executive Officer at Health Data Research UK (HDRUK), the UK’s national institute for health data science.
At 2020 Delivery (now The PSC) she was a director advising health organisations, universities and central government departments on strategy, transformation, capability building, and delivery planning. Prior to joining 2020 Delivery, Caroline was an Engagement Manager at McKinsey & Company and a Chartered Engineer Control and Electrical Engineer at ICI. Caroline holds an MBA from Harvard Business School and an MA and MEng from the University of Cambridge.
Nicola Broughton is a Senior Scientist at CPI, delivering high impact research, development, and innovation projects in HealthTech. With a background in cell biology, Nicola initially worked as an industrial laboratory chemist developing new products and formulations for an aerosol manufacturer. After moving to CPI in 2015, Nicola developed functional ink formulations, particularly those containing nanomaterials for flexible electronics. She now works to establish coating, printing, patterning, and deposition methods for a number of different applications including medical devices, wearable electronics and sensors.
Nicola has worked across several roles, including bid writing, project management and technical leadership of multi-disciplinary teams to facilitate the technical and process developments needed to advance products to market. Most recently, Nicola co-led the £8.7 million Health Tech Regulatory and Innovation Programme, providing a wide-ranging package of support to the UK HealthTech industry in a changing regulatory environment.
Martin Baxter FIEMA, CEnv, FRSA
IEMA – Institute of Environmental Management & Assessment
Martin Baxter is Policy and External Affairs Director and Deputy CEO at the Institute of Environmental Management and Assessment (IEMA). He works in the UK and internationally to support the transition to a low carbon, resource efficient and sustainable economy and reverse the decline of the natural environment.
Martin has national and international experience in developing and negotiating global and European environmental management standards and developing capacity for effective and widespread implementation. Martin heads the UK delegation to the International Organisation for Standardisation (ISO) on environmental management and chairs the ISO environmental management systems committee of ~100 countries. He is also vice-chair of the European Standards CEN/CENELEC Strategic Advisory Body on the Environment.
Martin is a Board member of IEMA and the Society for the Environment (SocEnv), and a member of the Government’s Green Jobs Delivery Group.
In his role, Nigel leads Bayer UK/I plans for digital health and how it can transform the health and wellbeing for patients, public and underpin the Life Science sector. Prior to joining Bayer, Nigel worked across the NHS delivering large-scale digital programmes, with his latest roles seeing him as Digital Programme Director for two STPs (precursor to ICS). Nigel looks forward to further enhancing collaboration between Bayer, the NHS and patients, and making Bayer a trusted industry partner. He is also committed to support UK start-ups/innovators and assist their expansion both locally and globally.
With more than ten years’ experience in QA/RA roles, Tim has breadth and depth of knowledge across the regulatory, engineering, clinical, design and development, and quality assurance disciplines. Tim has a passion for empowering innovation in medical devices, and brings insight and pragmatism to projects bringing complex lifesaving and life enhancing products to market.
Dr Jean Marc Feghali – Head of Research and Development at WeWALK
Being visually impaired and obtaining a PhD in the mobility of visually impaired people at Imperial College London, Jean Marc is driven by the life-changing potential of his research and its impact on assistive technology. Jean Marc leverages his findings in the development of the WeWALK smart cane, a TIME best invention of 2019, through managing multi-million-pound R&D collaborations with world-leading partners including Microsoft and RNIB.
Jean Marc also regularly advises on transport accessibility and sits on Transport for London’s IDAG advisory board for disability and inclusion, as well as conducting novel mobility research that has been recognised through an Imperial College Medal for Outstanding Achievement, the Walter Redlich Prize for Academic Excellence, and the Royal Institute of Navigation for an Outstanding Contribution to a More Navigable World.
Professor Emily Jefferson became the Chief Technology Officer (CTO) of Health Data Research UK in November 2022. She is seconded from her position as Professor of Health Data Science at the University of Dundee. She leads on the development and delivery of technology services to enable the provision of consistent and meaningful research access to health data. This includes the Health Data Research Innovation Gateway, which accelerates the discovery and access request management enhancing the ethical, secure, and transparent use of health datasets and other assets. Emily will lead the next stage of development which will include collaborating with Trusted Research Environment providers across the UK on federated analytics.
Emily had a track record of collaboration across HDR UK’s broad community of partners before joining as CTO, including her role as Director of the HDR Alleviate Pain Data Hub; as Co-Principal Investigator for the CO-CONNECT programme, as work package lead on the HDR UK Phenotypes Library and the HDR UK Multi-omics Project and as Primary Investigator on the HDR Scottish Data Federation Project and the HDR UK Biorepository Project.
Prior to her role as CTO, Emily was the Director of the Health Informatics Centre (HIC) at the University of Dundee for 10 years during which time she led a large team providing services and academic collaborations to over 700 different research projects covering health informatics, data science, data management, governance, and machine learning. She also held a part-time role at the University of Glasgow for 18 months.
Riam Kanso is the founder and CEO of Conception X; the UK’s leading venture programme for PhD students who want to build deep technology startups. Riam has a PhD in Neuroscience from Oxford University and has worked both in computational science and med tech; and has co-founded two startups before Conception X.
Since 2018 she has made it her mission to leverage the power of universities and PhD students to create companies that tackle global issues like energy and health. Conception X is currently the only independent cross-university platform that transforms PhD into ‘Venture Scientists’; scientists who transform original research into impactful and scalable products, bridging the gap between lab and market. CX has recruited students from over 40 universities and has enabled collaborations across the higher education sector in the facilitation of tech transfer.
Debora is Enhanc3D Genomics CEO and has a keen interest in disruptive technologies that have potential to benefit human healthcare. She brings a wealth of experience in technology development, together with a track record of successfully delivering large-scale projects in academia and industry. In previous roles Debora led a cancer signature discovery (Director at Cambridge Epigenetix), directed and managed laboratory research on large population studies (Head of laboratory, MRC Epidemiology, University of Cambridge) and worked on the development of the Oxford Nanopore’s technology. At Enhanc3D Genomics, Debora is driving the development of the technical platforms, establishing partnerships across the pharma and biotech industry, and advocating the advent of a 3D genomics era.
Megan Kelly is a passionate and dedicated healthcare professional with a focus on health technology, operations, and change management. With over 13 years of experience in diverse healthcare businesses, Megan adds value to mission-driven innovative organisations. She brings a wealth of knowledge and insight, with expertise in research, quality, operations, implementation, and strategy.
Megan is currently the Solutions Delivery Manager at Vinehealth, an oncology platform aiming to transform life with cancer through technology. Megan is responsible for leading the delivery and implementation of the platform to healthcare providers.
Prior to joining Vinehealth she worked at Aetna International (a CVS Health company), as Clinical Quality Lead, working with US and other global healthcare systems.
Previously, Megan worked in the NHS as an Operations Manager of a large cancer centre, and as a Therapeutic Radiographer.
Tim trained as a nephrologist and intensive care doctor in Oxford and is CEO of Cognitant Group, a company on a mission to empower people with information about their health and treatment options. He is current president of the Digital Health section at the Royal Society of Medicine, a non-executive director and adviser for several health tech companies and a mentor for the NHS clinical entrepreneur programme.
Jane Theaker is a companion diagnostics expert with a passion for using novel technologies, datasets and analytics to change the way we discover, develop and deliver drugs to patients. She has worked for the NHS, Zeneca Diagnostics, Astrazeneca, DxS, QIAGEN and the Laboratory of the Government Chemist (LGC). During her career Jane co-invented a real-time PCR technology at Zeneca Diagnostics that she and her team at QIAGEN later used to deliver FDA approved tests to support novel oncology drug launches. She was also an early proponent of NGS sequencing in Companion diagnostics. She is now the CEO of PBD Biotech, developers of Actiphage®, a phage-based test that identifies Mycobacterium tuberculosis (Mtb) in the blood – an early indication of ‘active’ TB disease. Actiphage has potential applications in latent TB screening and drug management.
After establishing TBAT in 2002 as a consultancy catering to the SME sector, Sam led the company’s evolution into the innovation-centric enterprise it is today. TBAT now specializes in supporting companies throughout the entire new product and process innovation cycle. Sam began his career as a graduate and manufacturing engineer at Rolls-Royce Aerospace before transitioning to Rolls Royce and Associates as a Development and Project Engineer. Currently, Sam heads up the Business Development and R&D Tax Credits side of the business.
Mike Lawton is a serial entrepreneur, who enjoys building early-stage, deep tech businesses in demanding environments. His biggest success to date is Oxford Space Systems, founded in 2013 and now seen as strategically important to the UK space sector and one of the highest-valued space start-ups in the UK. Currently a Co-Founder & Director in two new ventures:
Mike is a keen supporter of STEM subjects, with a particular passion for inspiring the next generation of entrepreneurial engineers and scientists.
* Barclay’s Bank UK Start-Up Tech Entrepreneur 2018
*Featured in Engineers Making a Difference Book
*Mentor for 2021 Santander Breakthrough Women Business Leaders’ Mentoring Programme
Graduating from Cambridge University with a degree in Natural Sciences, and with a PhD in Geophysics,
Steven began his Barclays career three decades ago. Over this time, he has held a variety of roles in
Operations and Change across a range of business and support areas. His positions have included: Head
of Risk, Head of Strategy and Planning, Head of Change, Chief Operating Officer for the UK Retail Bank,
Strategic Transformation Director and Chief Scientific Adviser and vice Chair of Barclays UK.
In addition, Steven joined the BUK Ventures team in 2018, and he is a visiting professor of Technology,
Behaviours and Information Strategy at Huddersfield University.
Last year, Steven became Head of Culture and Transformation for Barclays UK, reporting directly to the
CEO of Barclays UK.
Steven was instrumental at Barclays in creating and leading the Strategic Transformation team for 7
years which had a wide-ranging remit to drive cultural and digital transformation. This included
overseeing the launch of Barclays Eagle Labs, pioneering the re-use of branch and corporate space
offering access to co-working and business incubation spaces as well as access to equipment such as 3D
printers and laser cutters as well as training sessions and meeting space to benefit start-up
entrepreneurs, schools, community groups and high growth businesses. There are now 24 Eagle Labs
across the UK, with more in the pipeline.
Other initiatives prior to the Eagle Labs have included the launch of Barclays Digital Eagles, creating over
30,000 volunteers within Barclays across the UK, Europe and Africa, supporting communities in
becoming more digitally competent. Steven’s team were also at the forefront of several industry leading
initiatives, including driving forward the cheque image programme and lobbying government to change
legislation to enable this. The team also lead the work to make Barclays much more accessible to
disabled and elderly customers, including talking ATM’s, and high visibility debit cards. More recently
the team worked on the development of a special group, “AI Eagles” to promote and help
understanding of AI across the UK.
Steven is married with four boys and lives with his wife Caroline in West London.
Jane Kennedy joined Discovery Park as Chief Business Officer in June 2021. Her remit is to drive strong business growth through the strategic development of the 220 acre science park; building an innovation hub, fostering a collaborative community on site and driving knowledge exchange.
With a Communication Studies degree, Jane spent the early part of her career working in advertising and marketing. In 2005 she became Marketing Manager of Roslin Biocentre (famed as the home of Dolly the sheep, the world’s first cloned mammal) running the science park and learning about the needs of startup and growing life sciences companies.
As the first employee of BioCity Scotland, she was instrumental in converting an ex-pharma site into BioCity’s first venture outside of Nottingham, launching and co-chairing the Glasgow BioCorridor. Additionally she launched the University of Glasgow’s Clinical Innovation Zone – a centre built around Stratified Medicine and Imaging – at the Queen Elizabeth University Hospital.
Jane has held several Startup support roles assisting early-stage tech-based businesses to build their teams and attract investment. She lives just outside Edinburgh in Scotland and splits her time working from home and travelling to the Discovery Park site in Sandwich, Kent.
Frederick Manduca graduated from Georgetown University in 2017 and previously worked at a neuro oncology company before founding newfoundland Diagnostics during the pandemic in 2020. newfoundland has quickly grown into one of the UK’s leading providers of diagnostic tests and medical devices with clients including Amazon, NHS England and the Canadian Government
Luca Lipani is the Co-founder and CEO of Transdermal Diagnostics, a Medtech spinout company developing a wearable device for non-invasive and real-time monitoring of health biomarkers. Former scientist, he is one of the main drivers for Transdermal’s technology innovation with multidisciplinary expertise spanning from nanotechnology, chemistry, biophysics and pharmacy.
James heads Mills & Reeve’s multi-disciplinary life sciences practice. He supports businesses across the full product lifecycle, from start-up to commercialisation.
A key focus of his work is supporting clients on strategic contracting covering technology / IP in and out- licensing transactions, research collaborations, clinical trial agreements and long term partnering agreements. James also advises on sector regulation including pharma and medical device regulation, market access, borderline products, advertising and clinical trials.
Ellie Halliday (Data Privacy & Compliance Manager) joined Talking Medicines in July 2020 after obtaining a law degree from the University of Edinburgh. Ellie’s remit is to drive innovation whilst ensuring the company functions through strong compliance frameworks which are centred on ethics.
Jono is CEO and co-founder of QuantuMDx Group, a UK-based life sciences company developing transformational point-of-care molecular diagnostics. He is the inventor of QuantuMDx’s proprietary sample preparation, amplification and detection technologies. Jono is dedicated to tackling global issues such as equitable access to quality diagnostics and antimicrobial resistance. He has given a TED talk on AMR and was a diagnostics advisor for the O’Neill Review. He is also part of several UK government-led COVID-19 committees, including the Manufacturing Industry Coalition Working Group and the Molecular PoC Working Group. Jonathan was awarded European CTO of the Year in 2015.
Peter co-led the creation of the NHS Covid-19 App. A year later he left the Civil Service to develop that technology further and founded Proxximos. The company created a digital contact tracing solution for use in hospitals and care homes. These environments have chronic issues with communicable disease outbreaks, which consume beds, drive up costs, and cause poor patient outcomes. There is a virtuous circle to explore – digital contact tracing can highlight who to test, and testing can trigger digital contact tracing.
Pari is a senior innovation professional, who specialises in identifying, building and validating new opportunities for major global companies and emerging start-ups. He has 11 years of experience of leading innovation and strategy projects for many of the world’s largest medical device and pharmaceutical companies, with a focus on discovering opportunities through user, market and technology insights. He has worked within consulting and corporate environments, now for 8 of the top 20 medical device companies, with a focus on discovering and reacting to user, market and technology insights.
Pari has additionally led innovation and strategy programmes in multiple other industries, including FMCG, consumer health, drug delivery, surgical and critical care; specialising in life sciences and diagnostics. Through these wide-ranging experiences, he has created and used many different tools for innovation, to capture the lessons learned and to enable the efficient discovery of both innovative and robust new offerings in different markets.
By background, Pari has a BSc in Biochemistry and a PhD in Genetics, in which he concentrated on the commercialization of early-stage technologies.
I am a Clinical Scientist in Microbiology within Leeds Teaching Hospitals Trust and have been a Visiting Researcher at the University of Leeds since 2015.
I work within the Healthcare Associated Infections (HCAI) Research Group, a multi-organisational (LTHT, UoL, PHE) research team lead by Professor Mark Wilcox.
I obtained my PhD from the University of Leeds in 2001 on “Antibiotics and Clostridium difficile”
I undertook Post-Doctoral work on C. difficile infection from 2001-2005 at the University of Leeds
I trained as a Clinical Scientist in Microbiology in Leeds Teaching Hospitals Trust and was registered with the Health Care Professions Council in 2013.
Paul S Weston is passionate about keeping people out of hospital. As Review & Accreditations Director at ORCHA he gives healthcare professionals and consumers the confidence to recommend and benefit from digital health products that are safe, effective and secure. Paul and his team of Digital Health Assessors develop and maintain Reviews in 12 countries and continually monitor and assess over 3000 products a year.
Prior to joining ORCHA, Paul was Chief Operating Officer at Tiny Medical Apps (Developer of top ORCHA rated asthma app the Digital Health Passport). His work led to inclusion on healthcare frameworks (LPP, G-Cloud, HSSF); maintaining quality assurance certification (ISO 27001/13485, Cyber Essential Plus, DSPT); and product deployment to over 1000 patients in 16 healthcare organisations.
Paul’s commitment to improving health outcomes started with delivering regulation-heavy primary care developments – a journey that impacted over 275,000 patients over 19 years leading ISO9001 certified Architecture businesses. Having seen the growing, untenable demands of in-person healthcare provision, in 2018 he made the decision to explore the role that digital health technology can play in reducing demand on the built environment.
Paul is a London Tech Advocate and One HealthTech (Diversity & Inclusion) Fellow focusing on international partnerships.
Dr Ama Frimpong is a multi-award-winning engineer, who is Head of Product Development and leads Regulatory Strategy at 52 North Health Ltd.
She leads the company’s engineering teams and the development of NeutroCheck, a low-cost, transformative in vitro diagnostic which will support remote triage of cancer patients at risk of life-threatening neutropenic sepsis.
She has spent her career at the forefront of healthcare innovations and has significantly contributed to the technical development of a vast array of products and processes, as a consultant engineer and researcher. She holds a PhD in Medical and Biological Engineering from the University of Leeds and is the IET Young Woman Engineer of the Year for 2022.
Pete Waddingham is the National Net Zero Lead for The AHSN Network – an organisation that supports the 15 AHSNs across England in order to spread innovation at pace and scale within the NHS. Pete has spent the last five years working for the Yorkshire & Humber AHSN on innovation to support topics such as Cardiovascular Disease, Cancer and workforce training, as well as supporting innovators understand how to access the NHS and improve efficiency, effectiveness and quality of care. Prior to this Pete worked as an Operation Manager at the Yorkshire Wildlife Trust managing Spurn Nature Reserve. He has ten years’ experience of working within the NHS as a Commissioning Manager and also numerous years working within Local Government (Housing) and during his career has always tried to blend innovation, creative thinking with an understanding of the need to tackle climate change and achieve Net Zero.
Dr Robert Porter has held senior positions (CEO, CTO, COO) across a range of UK and International diagnostic companies, and served as an adviser to the UK Health Service for scale-up manufacturing for COVID rapid testing and has helped with the development and launch of many COVID diagnostic test.
Dr Robert Porter established RAPIvD ltd in 2018, with more than 30 years of experience in the field of bio-diagnostics. Rob was keen to establish his own company to provide the expertise and facilities required by customers and collaborating partners to advance the technologies and availability of lateral flow and similar devices.